维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Huangjue Lin"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	HOXA13 serves as a biomarker to predict neoadjuvant therapy efficacy in advanced colorectal cancer patients显示文摘Neoadjuvant therapy(NAT)for advanced colorectal cancer(ACRC)is a kind of well-evidenced therapy,yet a portion of ACRC patients have poor therapeutic response.To date,no suitable biomarker used for assessing NAT efficacy has been reported.Here,we collect 72 colonoscopy biopsy tissue specimens from ACRC patients before undergoing NAT and investigate the relationship between HOXA13 expression and NAT efficacy.The results show that HOXA13 expression in pretreated tumor specimens is negatively associated with tumor regression(P<0.001)and progression-free survival(P<0.05)in ACRC patients who underwent NAT.Silencing of HOXA13 or its regulator HOTTIP significantly enhances the chemosensitivity of colorectal cancer(CRC)cells,leading to an increase in cell apoptosis and the DNA damage response(DDR)to chemotherapeutic drug treatment.In contrast,HOXA13 overexpression causes a significant increase in chemoresistance in CRC cells.In summary,we find that the HOTTIP/HOXA13 axis is involved in regulating chemotherapeutic sensitivity in CRC cells by modulating the DDR and that HOXA13 serves as a promising marker for NAT efficacy prediction in ACRC patients.	Shuanghui Liu Rui Zhang Zhengquan Yang Yajiao Wang Xingxiu Guo Youjuan Zhao Huangjue Lin Youqun Xiang Chunming Ding Zhixiong Dong Chang Xu	2023	Acta Biochimica et Biophysica Sinica2023，55，2：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费